Showing 5661-5670 of 8791 results for "".
- FDA Approves Valeant's SILIQ For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-valeants-siliq-for-moderate-to-severe-plaque-psoriasis/2458283/The FDA has approved the Biologics License Application (BLA) for Valeant Pharmaceutical's SILIQ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis. SILIQ is indicated for the treatment of mo
- New From Alastin Skincare: HydraTint ProMineral Broad Spectrum Sunscreen SPF 36https://practicaldermatology.com/news/new-from-alastin-skincare-hydratint-promineral-broad-spectrum-sunscreen-spf-36/2458289/ALASTIN Skincare, Inc. is introducing HydraTint ProMineral Broad Spectrum Sunscreen SPF 36. The lightweight matte formula is oil-free, absorbs quickly and has a tint. It also comprises an air pollution shield to protect skin from environmental aggresso
- Intramuscular Flu Shots May Mitigate Staph Risk In AD Patientshttps://practicaldermatology.com/news/intramuscular-flu-shots-may-be-better-for-ad-patients/2458290/Staphylococcus colonization of atopic dermatitis patients’ skin is associated with a weaker response to intradermal flu shots, according to a new study which suggests that intramuscular flu vaccines may be more effective in this group. The research, funded by the Natio
- Study Finds Increased Incidence of SCC Among Patients Treated with Biologics for Psoriasishttps://practicaldermatology.com/news/study-find-increased-incidence-of-scc-among-patients-treated-with-biologics-for-psoriasis/2458296/A recent study published in the Journal of the American Academy of Dermatology sought to estimate the overall malignancy rate (excluding non-melanoma skin cancere [NMSC]) and NMSC rate among 5,889 patients with systemically
- Realm Therapeutics Submits Investigational New Drug Application for PR022 for Atopic Dermatitishttps://practicaldermatology.com/news/realm-therapeutics-submits-investigational-new-drug-application-for-pr022-for-atopic-dermatitis/2458305/Realm Therapeutics plc submitted its first investigational new drug (IND) application to the FDA for PR022 as a novel treatment for atopic dermatitis (AD). Pending acceptance, the IND will enable Realm to initiate a Phase 2a proof-of-concept trial for patients with atopic dermatitis.
- Dr. David Norris Named New ASA Presidenthttps://practicaldermatology.com/news/dr-david-norris-named-new-asa-president/2458304/David Norris, MD, Chairman of the Department of Dermatology at the University of Colorado School of Medicine, is the new President of American Skin Association (ASA). Dr. Norris has been a part of ASA since 1997, serv
- New Plush Wonder Duck Toy Benefits Children's Skin Disease Foundation and Camp Wonderhttps://practicaldermatology.com/news/new-plush-wonder-duck-toy-benefits-childrens-skin-disease-foundation-and-camp-wonder/2458308/A plush version of Camp Wonder’s mascot, Wonder Duck, is now available for purchase, with 100% of the proceeds going to the Children's Skin Disease Foundation. Camp Wonder is a summer camp for children with serious and fatal skin condition
- Sun Pharma Introduces Leave Acne Behind Patient Initiativehttps://practicaldermatology.com/news/sun-pharma-introduces-leave-acne-behind-patient-initiative/2458310/Sun Pharma introudced a new initiative— “Leave Acne Behind™" — to educate patients and create awareness of severe recalcitrant nodular acne (SRNA). Sun Pharma reports that out of all of the prescription- treated acne cases today, 20 percent represent severe acne condi
- FDA Approves RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For Persistent Facial Erythema Associated With Rosaceahttps://practicaldermatology.com/news/fda-approves-rhofade-oxymetazoline-hydrochloride-cream-1-for-persistent-facial-erythema-associated-with-rosacea/2458315/The FDA has approved Allergan's RHOFADE™ cream for the topical treatment of persistent facial erythema associated with rosacea in adults. Approval was based on two clinical studies that evaluated the primary efficacy endpoint on day 29. Among the estimated 16 million aAmericans
- First Patient Treated in Dermata Therapeutics Phase 2 Acne Rosacea Clinical Studyhttps://practicaldermatology.com/news/first-patient-treated-in-dermata-therapeutics-phase-2-acne-rosacea-clinical-study/2458316/The first patient has been dosed in Dermata Therapeutics’s Phase 2 acne rosacea study of DMT210, a topical gel specifically developed to downregulate the proinflammatory cytokines in the skin responsible for the inflammation and redness seen in acne ro